Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib

Author(s):
Reichardt, P.; Blay, J.Y.; Gelderblom, H.; Schlemmer, M.; Demetri, G.D.; Bui-Nguyen, B.; McArthur, G.A.; Yazji, S.; Hsu, Y.; Galetic, I.; Rutkowski, P.
Published
2012
Publication type
Article / Letter to editor
gastrointestinal stromal tumorsGISTimatinibnilotinibsunitinibtyrosine kinase inhibitor
Date issued
2012-07-31
Language
English
Is part of
Annals of Oncology (2012), Vol. 23, no. 7, p. 1680-1687
hdl
1887/97533
doi
10.1093/annonc/mdr598